Fixed-Drug Combinations as First-Line Treatment for Hypertension

Progress in Cardiovascular Diseases

Volumn 48, Issue 6, 2006, Pages 416-425

  Rosenthal, Talma ^a,b   Gavras, Irene ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPROSARTAN; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INDAPAMIDE; IRBESARTAN; LOSARTAN; METHYLDOPA; METOPROLOL; NADOLOL; PERINDOPRIL; PROPANOL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TIMOLOL; UNINDEXED DRUG; VALSARTAN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; INCIDENCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; MONOTHERAPY; MULTICENTER STUDY; POLYPHARMACY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; TITRIMETRY; UNSPECIFIED SIDE EFFECT; DECISION MAKING; DRUG COMBINATION; REVIEW; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; DECISION MAKING; DRUG COMBINATIONS; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 33745174496     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2006.03.003     Document Type: Article

References (69)

1. Hutchison J.C. Long-term treatment of hypertension with a preparation combining rauwolfia and bendroflumethiazide. Med. Times 95 (1967) 860-868
2. Freis E.D. Hypertension: Challenge in preventive medicine. Prev. Med. 2 (1973) 7-9
3. Moser M. Evolution of the treatment of hypertension from the 1940s to JNC V. Am. J. Hypertens. 10 (1997) 2S-8S
4. Philipp T., Anlauf M., Distler A., et al. Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: Results of the HANE study. HANE Trial Research Group. BMJ 315 (1997) 154-159
5. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 (2002) 995-1003
6. Mugellini A., Dobovisek J., Planinc D., et al. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: Results of a randomized trial. Clin. Ther. 26 (2004) 1419-1426
7. Guidelines Committee 2003. European Society of Hypertension European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21 (2003) 1011-1053
8. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289 (2003) 2560-2572
9. Weir M.R. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am. J. Hypertens. 18 (2005) 100S-105S (suppl)
10. Salerno C.M., Demopoulos L., Mukherjee R., et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J. Clin. Hypertens. 6 (2004) 614-620
11. Ruilope L.M., Malacco E., Khder Y., et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The VAST study. Clin. Ther. 27 (2005) 578-587
12. Conlin P.R., Gerth W.C., and Fox J. Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin. Ther. 23 (2001) 1999-2010
13. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev. Cardiovasc. Ther. 1 (2003) 43-50
14. Cheng A., and Frishman W.H. Use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium channel blockers. J. Clin. Pharmacol. 38 (1998) 477-491
15. Mugellini A., Vaccarella A., Celentano A., et al. Fixed combination of manidipine and delapril in the treatment of mild to moderate essential hypertension: Evaluation by 24-hour ambulatory blood pressure monitoring. Blood Press. 14 (2005) 6-13 (suppl 1)
16. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. JAMA 288 (2002) 2981-2997
17. Rosei E.A., and Rizzoni D. DIMS II (Delapril-Indapamide Multicenter Study II): Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: A randomised, multicentre, controlled study. J. Hum. Hypertens. 17 (2003) 139-146
18. London G.M., Asmar R.G., O'Rourke M.F., et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: Comparison with atenolol. J. Am. Coll. Cardiol. 43 (2004) 92-99
19. Krzesinski J.M. The drug of the month: A new antihypertensive association: Preterax, low doses of ACE inhibitor and thiazide in the same pill. Rev. Med. Liege 59 (2004) 601-606 (French)
20. Lacourciere Y., and Poirier L. Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension. Am. J. Hypertens. 16 (2003) 1036-1042
21. Mancia G., and Omboni S. Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients. Blood Press. 13 (2004) 11-17 (suppl 2)
22. Maillard M., and Burnier M. Telmisartan/hydrochlorothiazide: A new fixed dose combination. Expert Rev. Cardiovasc. Ther. 3 (2005) 375-386
23. Kjeldsen S.E., Os I., Høieggen A., et al. Fixed-dose combinations in the management of hypertension. Am. J. Cardiovasc. Drugs 5 (2005) 17-22
24. Elliott W.J., Calhoun D.A., DeLucca P.T., et al. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: Data from a multicenter, randomized, double-blind, 12-week trial. Clin. Ther. 23 (2001) 1166-1179
25. Gillespie E.L., White C.M., Kardas M., et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 28 (2005) 2261-2266
26. Abuissa H., Jones P.G., Marso S.P., et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes a meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 46 (2005) 821-826
27. Aksnes T.A., Reims H.M., Kjeldsen S.E., et al. Antihypertensive treatment and new-onset diabetes mellitus. Curr. Hypertens. Rep. 7 (2005) 298-303
28. Boner G., Cooper M.E., McCarroll K., et al. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia 48 (2005) 1980-1987
29. Bramlage P., Pittrow D., and Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: An observational study in 16,600 patients in primary care. Curr. Med. Res. Opin. 20 (2004) 1625-1631
30. Atkins R.C., Briganti E.M., Lewis J.B., et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am. J. Kidney Dis. 45 (2005) 281-287
31. Campese V.M., Shaohua Y., and Huiquin Z. Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension 46 (2005) 533-539
32. Schupp M., Janke J., Clasen R., et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109 (2004) 2054-2057
33. Siddiqui M.A., and Plosker G.L. Fixed-dose combination enalapril/nitrendipine: A review of its use in mild-to-moderate hypertension. Drugs 64 (2004) 1135-1148
34. Cvetkovic R.S., and Plosker G.L. Ramipril/felodipine extended-release fixed-dose combination: A review of its use in the management of essential hypertension. Drugs 65 (2005) 1851-1868
35. Bakris G.L. Protecting renal function in the hypertensive patient: Clinical guidelines. AJH 18 (2005) 112S-119S
36. Fogari R., Malamani G.D., Zoppi A., et al. Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J. Hum. Hypertens. 17 (2003) 207-212
37. Bakris G.L., and Weir M.R. Achieving goal blood pressure in patients with type 2 diabetes: Conventional versus fixed-dose combination approaches. J. Clin. Hypertens. (Greenwich) 5 (2003) 202-206
38. Jamerson K.A., Nwose O., Jean-Louis L., et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am. J. Hypertens. 17 (2004) 495-501
39. Reynolds N.A., Wagstaff A.J., and Keam S.J. Trandolapril/verapamil sustained release: A review of its use in the treatment of essential hypertension. Drugs 65 (2005) 1893-1914
40. Lauler D.P. European experience with spironolactone and thiazide diuretic as antihypertensive therapy. Am. J. Cardiol. 65 (1990) 18K-19K
41. Svendsen U.G., Ibsen H., Rasmussen S., et al. Effects of combined therapy with amiloride and hydrochlorothiazide on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in hypertensive patients. Eur. J. Clin. Pharmacol. 30 (1986) 151-156
42. Yusuff K.B., and Balogun O. Physicians' prescribing of anti-hypertensive combinations in a tertiary care setting in southwestern Nigeria. J. Pharm. Pharm. Sci. 8 (2005) 235-242
43. Eide I.K., Torjesen P.A., Drolsum A., et al. Low-renin status in therapy-resistant hypertension: A clue to efficient treatment. J. Hypertens. 22 (2004) 2217-2226
44. Goodfellow R.M., and Westberg B. The treatment of high blood pressure in the elderly: A multi-centre evaluation of a fixed combination of metoprolol and hydrochlorothiazide ("Co-Betaloc") in general practice. Curr. Med. Res. Opin. 7 (1981) 536-542
45. Young J.H., VandenBurg M.J., Isitt V.L., et al. Comparison of a fixed ratio combination of hydrochlorothiazide, amiloride and timolol ("Moducren") given once versus twice daily in mild to moderate hypertension. Pharmatherapeutica 4 (1984) 64-68
46. Benetos A., Adamopoulos C., Argyriadis P., et al. Clinical results with bisoprolol 2.5 mg/hydrochlorothiazide 6.25 mg combination in systolic hypertension in the elderly. J. Hypertens. 20 (2002) S21-S25 (suppl)
47. Hildemann S.K., Fischer H.M., Pittrow D., et al. Antihypertensive first-line and add-on treatment with a fixed controlled release combination of metoprololsuccinate/hydrochlorothiazide. Prospective doctor's office observational study in 14,964 patients. Fortschr. Med. Orig. 121 (2003) 27-32
48. Krivitzky A., Nguyen G., Gaudouen Y., et al. Atenolol/nifedipine combination: Efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension. Drugs 56 (1998) 31-43 (French, suppl 2)
49. Haria M., Plosker G.L., and Markham A. Felodipine/metoprolol: A review of the fixed dose controlled release formulation in the management of essential hypertension. Drugs 59 (2000) 141-157
50. Gavras I., and Rosenthal T. Combination therapy as first-line treatment for hypertension. Curr. Hypertens. Rep. 6 (2004) 267-272
51. Brown M.J., Cruickshank J.K., Dominiczak A.F., et al. Better blood pressure control: How to combine drugs. J. Hum. Hypertens. 17 (2003) 81-86
52. Neutel J.N., Smith D.H.G., Weber M.A., et al. Initial combination therapy in older patients with systolic hypertension; results of SELECT (systolic evaluation of Lotrel Efficacy and Comparative Therapies) study (abstract). Am. J. Hypertens. 17 (2004) 183A (abstract P-409)
53. Bakris G.L., Weir M.R., and on behalf of the study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: Conventional versus fixed-dose combination approaches. J. Clin. Hypertens. 5 (2003) 202-209
54. Jamerson K.A., Bakris G.L., Wun C.-C., et al. Rationale and design of the Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial. The first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am. J. Hypertens. 17 (2004) 793-801
55. Bakris G.L., Toto R.D., and McCullough P.A. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J. Hum. Hypertens. 19 (2005) 139-144
56. Schmieder R.E. Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hypertension. Expert Opin. Pharmacother. 5 (2004) 2303-2310
57. Weber M. The telmisartan PRogramme of research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J. Hypertens. 21 (2003) S37-S46 (suppl)
58. Patel A., Chalmers J., and Poulter N. ADVANCE: Action in diabetes and vascular disease. J. Hum. Hypertens. 19 (2005) S27-S32
59. BENEDICT Group. The Bergamo NEphrologic DIabetes Complications Trial (BENEDICT): Design and baseline characteristics. Control. Clin. Trials 24 (2003) 442-461
60. Teo K., Yusuf S., Sleight P., et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am. Heart J. 148 (2004) 52-61
61. Sleight P. The ONTARGET/TRANSCEND Trial Programme: Baseline data. Acta Diabetol. (2005) 42S50-42S56 (suppl 1)
62. Coca A., Calvo C., Sobrino J., et al. Once-daily fixed-combination irbesartan 300 mg/hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin. Ther. 25 (2003) 2849-2864
63. Law M.R., Wald N.J., Morris J.K., et al. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 326 (2003) 1427-1434
64. Waeber B. Very-low-dose combination: A first-line choice for the treatment of hypertension?. J. Hypertens. 21 (2003) S3-S10 (suppl)
65. Meredith P.A. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: Potential benefits beyond the antihypertensive effect. Am. J. Cardiovasc. Drugs 5 (2005) 171-183
66. Bakris G.L. Preventing hypertensive kidney disease: The critical role of combination therapy. AJH 18 (2005) 93S-94S
67. Wald N.J., and Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 (2003) 1419-1424
68. Fahey T., and Brindle P. The polypill and cardiovascular disease. BMJ 330 (2005) 1035-1036
69. Smith R. Take forward the polypill idea, concludes expert committee. BMJ 330 (2005) 8